ASLAN Pharmaceuticals Limited(ASLN)

Sector:

Healthcare

Description:

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Current Price

$4.20

RSI

63.92

Market Capitalization:

185.9M

Beta:

2.388

Volume:

29,534

Analyst Target Price:

$ 8

Economiic Fair Price:


August 05, 2022
September 30, 2021
Q3
N/A
N/A
N/A
N/A
N/A
100.5M
31.2M
-0.429
N/A
0.005
-0.655

$ 3M
-73.89 %
$ 11.5M

$ -34M
-126.09 %
$ -15.1M
41.65 %
$ -25.8M
58.75 %
$ -62.6M
-76.63 %
$ -35.4M
-488.08 %
$ -6M

$ -46.7M
-418.21 %
$ -9M

News

Press Releases

Notable Dates